These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1547798)

  • 1. Epirubicin: clinical toxicity during the phase II program in endometrial and cervical cancer.
    Calero F; Jimeno J; Rodríguez-Escudero F; Asins Codoner J; Mendana J; Iglesias J; Murillo F; Ugalde F; Armas A; Rementería A
    Eur J Gynaecol Oncol; 1992; 13(1):83-9. PubMed ID: 1547798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single agent epirubicin in squamous cell cervical cancer. A phase II trial.
    Calero F; Rodriguez-Escudero F; Jimeno J; Mendaña J; Iglesias J; Murillo F; Ugalde F; Armas A; Rementeria A; Asins J
    Acta Oncol; 1991; 30(3):325-7. PubMed ID: 2036241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).
    Chauvergne J; Fumoleau P; Cappelaere P; Metz R; Armand JP; Chevallier B; Kerbrat P; de Forni M; Lhommé C; Roche H
    Eur J Cancer; 1993; 29A(3):350-4. PubMed ID: 8398333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma.
    Lissoni A; Gabriele A; Gorga G; Tumolo S; Landoni F; Mangioni C; Sessa C
    Ann Oncol; 1997 Oct; 8(10):969-72. PubMed ID: 9402169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
    Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncologico (GGETO).
    Calero F; Asins-Codoñer E; Jimeno J; Rodriguez Escudero F; Mendaña J; Iglesias J; Matía F; Armas A; Díaz-Castellanos R; Garzón J
    Eur J Cancer; 1991; 27(7):864-6. PubMed ID: 1834118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracyclines in non-small-cell lung cancer: do they have a therapeutic role?
    Martoni A; Guaraldi M; Piana E
    Ann Oncol; 1999; 10 Suppl 5():S19-23. PubMed ID: 10582134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin.
    D'Agostino G; Distefano M; Greggi S; Salerno M; Ferrandina G; Poerio A; Mancuso S; Scambia G
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):256-60. PubMed ID: 11935219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary chemotherapy for locally advanced uterine cervical carcinoma.
    Cheirsilpa A; Kosiyatrakul T; Benjachai W; Tangkrutt S; Puriphat S
    Gan To Kagaku Ryoho; 1992 Jul; 19(8 Suppl):1224-32. PubMed ID: 1514836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma.
    Vermorken JB; ten Bokkel Huinink WW; Kobierska A; van der Burg ME; Forni M; Piccart MJ; van der Putten E
    Oncology; 1999 Jul; 57(1):10-6. PubMed ID: 10394119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II study of epirubicin on gastric cancer--a cooperative study of the Tokai Cancer Chemotherapy Group].
    Kimura K; Suga S; Kano H; Sakakibara K; Hayashi T; Nakai T; Nagano I; Yokoyama Y; Morise K; Hayakawa M
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2440-5. PubMed ID: 3460530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.
    Carmo-Pereira J; Costa FO; Miles DW; Henriques E; Richards MA; Rubens RD
    Cancer Chemother Pharmacol; 1991; 27(5):394-6. PubMed ID: 1999000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
    Brambilla C; Rossi A; Bonfante V; Ferrari L; Villani F; Crippa F; Bonadonna G
    Cancer Treat Rep; 1986 Feb; 70(2):261-6. PubMed ID: 3456271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with intermediate-dose (110-120 mg/m2) epirubicin.
    Hickish T; Cunningham D; Haydock A; Coombes RC
    Cancer Chemother Pharmacol; 1989; 24(1):61-4. PubMed ID: 2720892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of high dose epirubicin in unresectable non small cell lung cancer.
    Smit EF; Berendsen HH; Piers DA; Smeets J; Riva A; Postmus PE
    Br J Cancer; 1992 Mar; 65(3):405-8. PubMed ID: 1313691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
    Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
    Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group.
    Quoix EA; Giaccone G; Jassem J; Karnicka H; Wiatr E; Cortes-Funes H; Roozendaal KJ; Kirkpatrick A; Evrard D; van Zandwijk N
    Eur J Cancer; 1992; 28A(10):1667-70. PubMed ID: 1327019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer.
    Neri B; Pacini P; Bartalucci S; Moroni F; Menchi I; Cappellini M
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):388-91. PubMed ID: 2793274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC).
    Holdener EE; Hansen HH; Høst H; Bruntsch U; Cavalli F; Renard J; Pinedo HM; Rozencweig M
    Invest New Drugs; 1985; 3(1):63-6. PubMed ID: 3857219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.